Stock comparison
ELI LILLY & Co is 503.1x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.119 T vs $2.22 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 503.1x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.119 T vs $2.22 B).
Market value leader
LLY
ELI LILLY & Co is 503.1x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.119 T vs $2.22 B).
Revenue leader
LLY
DAWN: $158.18M vs LLY: $65.18B.
Profit leader
LLY
DAWN: -$107.32B vs LLY: $20.64B.
Margin leader
LLY
DAWN: -67847.2% vs LLY: 31.7% net margin.
| Metric | DAWN | LLY |
|---|---|---|
| Market cap | $2.22 B | $1.119 T |
| US-listed rank | #2048 | #10 |
| Revenue (latest FY) | $158.18M | $65.18B |
| Net income (latest FY) | -$107.32B | $20.64B |
| Net margin | -67847.2% | 31.7% |
| P/E (trailing FY) | - | 54.2x |
| SEC filings | 493 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 503.1x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.119 T vs $2.22 B).
In their latest fiscal years, Day One Biopharmaceuticals, Inc. reported $158.18M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Day One Biopharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.